July 2018 Bonus Mid-Year Edition

July 2018 Bonus Mid-Year Edition

Volume 4, Issue 9

This bonus issue features a look at the most recent changes to Maintenance of Certification programs, highlights from recent hematology/oncology meetings, and more.

Table of Contents

July 2018 Bonus Issue

American Cancer Society Awards $2.6 Million for Immunotherapy Research, and more

Friday, July 20th, 2018
Remembering Past ASH President George Stamatoyannopoulos (1934 - 2018) George Stamatoyannopoulos, MD, DrSci, a professor of medical genetics at the University of Washington who pioneered...

July 2018 Bonus Issue

MOC Machinations

Friday, July 20th, 2018
The changing landscape of MOC Knowledge Check-Ins and how the American Society of Hematology continues pursuing a pragmatic approach to the MOC process.  The past...

July 2018 Bonus Issue

EURO-SKI: Can Patients With CML Stop Tyrosine Kinase Inhibitors?

Friday, July 20th, 2018
Treatment with tyrosine kinase inhibitors (TKIs) like imatinib, nilotinib, and dasatinib, has increased the rates of survival and response over previously available therapies for...

NYC Firefighters Exposed to World Trade Center Disaster Have Increased Myeloma Risk

Friday, July 20th, 2018
New York City firefighters who were exposed to chemicals released into the environment following the World Trade Center (WTC) attacks on September 11, 2001,...

Presence of Minimal Residual Disease Predicts Relapse and Survival in AML

Friday, July 20th, 2018
For patients with acute myeloid leukemia (AML), the detection of molecular minimal residual disease (MRD) in patients achieving morphologic complete remission (CR) was associated...

Complete Mutation Clearance Predicts Longer Survival and Lower Relapse Risk in AML

Friday, July 20th, 2018
Somatic mutation clearance (MC) at complete remission (CR) of acute myeloid leukemia (AML) was associated with improved survival and reduced risk of relapse, according...

Psychiatric Comorbidities of Myeloma Lead to High Health-Care Costs

Friday, July 20th, 2018
Many patients with multiple myeloma (MM) have a high risk for developing psychiatric comorbidities and, according to a study published in Blood Advances, managing...

FDA Opens Communication Lines Between Drug Makers and Insurers

Friday, July 20th, 2018
The U.S. Food and Drug Administration (FDA) has issued final guidance documents outlining the types of information that drug companies may share with insurers,...

First Pegfilgrastim Biosimilar Receives Approval

Friday, July 20th, 2018
The U.S. Food and Drug Administration (FDA) has approved pegfilgrastim-jmdb, a biosimilar version of pegfilgrastim, which is indicated to decrease the duration of neutropenia...

Scientists Engineer Artificial Bone Tissue

Friday, July 20th, 2018
Researchers have developed an artificial bone marrow niche, in which hematopoietic and progenitor cells are able to multiply and remain functional for several days,...

FDA Approves Avatrombopag for Thrombocytopenia

Friday, July 20th, 2018
The U.S. Food and Drug Administration (FDA) has approved avatrombopag for the treatment of thrombocytopenia in adults with chronic liver disease who are scheduled...

WHO Identifies “Essential” Lab Tests

Friday, July 20th, 2018
The World Health Organization (WHO) published a new list of 113 diagnostic tests that it considers “essential” to every health-care system. Called the Essential...

July 2018 Bonus Issue

Axicabtagene Ciloleucel Moves to Acute Lymphocytic Leukemia

Friday, July 20th, 2018
Axicabtagene ciloleucel, which in October 2017 became the first chimeric antigen receptor (CAR) T-cell therapy approved for the treatment of B-cell lymphoma, showed “promising...

Moxetumomab Pasudotox: An Alternative to Chemotherapy in Hairy Cell Leukemia

Friday, July 20th, 2018
In a pivotal phase III clinical trial of moxetumomab pasudotox in patients with relapsed/refractory hairy cell leukemia (HCL), three-quarters of participants responded to treatment....

Phase III BFORE Trial: Bosutinib Beats Imatinib for Frontline CML Treatment

Friday, July 20th, 2018
Patients with previously untreated chronic myeloid leukemia (CML) who received bosutinib were more likely than those who received imatinib to respond to treatment and...

bb2121: Is CAR T-Cell Therapy Moving to Myeloma?

Friday, July 20th, 2018
Chimeric antigen receptor (CAR) T-cell therapies have revolutionized the treatment of acute lymphocytic leukemia and non-Hodgkin lymphoma, and might now be poised to shake...

Acalabrutinib Induces Durable Response in Patients With Waldenström Macroglobulinemia

Friday, July 20th, 2018
In a phase II study of patients with Waldenström macroglobulinemia (WM), treatment with the highly selective Bruton tyrosine kinase (BTK) inhibitor acalabrutinib led to...

Evaluating FT-2102 in IDH1-Mutated AML or MDS

Friday, July 20th, 2018
According to interim data from a first-in-human phase I trial, treatment with FT-2102, a selective inhibitor of mutant IDH1, was tolerable and demonstrated anti-leukemic...

Synthetic Hepcidin Options Safe in Patients With Iron Disorders, But Efficacy Data Still Preliminary

Friday, July 20th, 2018
Two studies presented at the 23rd Congress of the European Hematology Association examined the safety and pharmacokinetics of two synthetic hepcidin options for the...

Higher Complete Response Rates With Polatuzumab Vedotin, Bendamustine, and Rituximab Combo in DLBCL

Friday, July 20th, 2018
Adding polatuzumab vedotin (an antibodydrug conjugate targeting CD79b-positive cells) to the combination of bendamustine and rituximab (BR) extended survival and increased complete responses (CRs)...

Fostamatinib Increases Hemoglobin Levels in Warm Antibody Autoimmune Hemolytic Anemia

Friday, July 20th, 2018
According to findings from a phase II SOAR study presented at the 23rd Congress of the European Hematology Association, twice-daily fostamatinib offered short-term improvement...

SHARE